Decreased sensitivity of drug-resistant cells towards T cell cytotoxicity

Leukemia

Volumn 13, Issue 3, 1999, Pages 410-418

  Classen, C F ^a   Fulda, S ^a   Friesen, C ^a   Debatin, K M ^a,b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

APO 1; Apoptosis; Cytotoxicity; Drug resistance; LAK cells; Resistance

Indexed keywords

DOXORUBICIN; FAS ANTIGEN; GRANZYME B; PERFORIN;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXIC T LYMPHOCYTE; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; T CELL LEUKEMIA; T LYMPHOCYTE; TARGET CELL;

EID: 0033012524     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401335     Document Type: Article

References (40)

1. Griffiths GM. The cell biology of CTL killing. Curr Opin Immunol 1995; 7: 343-348.
2. Komada Y, Zhou Y-W, Zhang X-L, Chen T-X, Tanaka S, Azuma E, Sakurai M. Fas/APO-1 (CD95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukemic cells induced by interleukin-2-activated T cells. Br J Haematol 1997; 96: 147-150.
3. Debatin KM. Cytotoxic drugs, programmed cell death and the immune system. Defining new roles in an old play. J Natl Cancer Inst 1997; 89: 750-751.
4. Friesen C, Herr I, Krammer P, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 1996; 2: 574-577.
5. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) mediates drug induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-3829.
6. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997; 90: 3118-3129.
7. Knight CRL, Rees RC, Platts A, Johnson T, Griffin M. Interleukin-2-activated human effector lymphocytes mediate cytotoxicity by inducing apoptosis in human leukemia and solid tumor target cells. Immunology 1993; 79: 535-541.
8. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein, P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.
9. Debatin KM. Disturbances of the CD95 (APO-1/Fas) system in disorders of lymphohematopoietic cells. Cell Death Differ 1996; 3: 185-189.
10. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387: 773-776.
11. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the Bcl 2 family and cell death. Blood 1996; 88: 386-401.
12. Stotzer OJ, Nüssler V, Darsow M, Gullis E, Pelka-Fleischer R, Scheel U, Wilmanns W. Association of bcl-2, bax, bcl-xL and interleukin-1β-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 1996; 10 (Suppl. 3): S18-S22.
13. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell function is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 651-652.
14. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
15. Lowin B, Peitsch MC, Tschopp J. Perforin and granzymes: crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity. Curr Top Microbiol Immunol 1995; 198: 1-24.
16. Lee RK, Spielman J, Zhao DY, Olsen KJ, Podack ER. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 1996; 157: 1919-1925.
17. Froelich CJ, Orth K, Turbov J, Seth P, Gottlieb R, Babior B, Shah GM, Bleackley RC, Dixit V, Hanna WL. New paradigm for lymphocyte granule-mediated cytotoxicity. J Biol Chem 1996; 271: 29073-29079.
18. Shi L, Mai S, Israels S, Browne K, Trapani J, Greenberg AH. Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J Exp Med 1997; 185: 855-866.
19. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995; 377: 446-448.
20. Shi L, Chen G, MacDonald G, Bergeron L, Li H, Miura M, Rotello RJ, Miller DK, Li P, Seshadri T, Yuan J, Greenberg AH. Activation of an interleukin 1 converting enzyme-dependent apoptosis pathway by granzyme B. Proc Natl Acad Sci USA 1996; 93: 11002-11007.
21. Van de Craen M, Van den brande I, Declerq W, Irmler M, Beyaert R, Tschopp J, Fiers W, Vandenabeele P. Cleavage of caspase family members by granzyme B: a comparative study in vitro. Eur J Immunol 1997; 27: 1296-1299.
22. Shresta S, Russell JH, Ley TJ. Mechanisms responsible for granzyme B-independent cytotoxicity. Blood 1997; 89: 4085-4091.
23. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (APO-1/Fas) system in drug resistant cells. Leukemia 1997; 11: 1833-1841.
24. Renvoizé C, Roger R, Moulian N, Bertoglio J, Bréard J. Bcl-2 expression in target cells leads to functional inhibition of caspase-3 protease family in human NK and lymphokine-activated killer cell granule-mediated apoptosis. J Immunol 1997; 159: 126-134.
25. Micheau O, Solary E, Hammann A, Martin F, Dimanchew-Boitrel M-T. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 1997; 89: 783-789.
26. Bohlen H, Manzke O, Patel B, Moldenhauer G, von Fliedner V, Diehl V, Tesch H. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 1993; 53: 4310-4314.
27. Kroesen BJ, Wellenberg GJ, Bakker A, Helfrich W, The TH, de Leij L. The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity. Br J Cancer 1996; 73: 721-727.
28. Csóka M, Strauss G, Debatin KM, Moldenhauer G. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3 × CD19 bispecific antibody. Leukemia 1996; 10: 1765-1772.
29. Koopman G, Reutelingsperger CPM, Kuijten GAM, Keehnen RMJ, Pals ST, van Oers MHJ. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
30. Radcliff G, Waite R, LeFevre J, Poulik MD, Callewaert DM. Quantification of effector/target conjugation involving natural killer (NK) or lymphokine activated killer (LAK) cells by two-colour flow cytometry. J Immunol Meth 1991; 139: 281-292.
31. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled annexin V. J Immunol Meth 1995; 184: 39-51.
32. Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH. Autocrine T cell suicide mediated by APO-1 (Fas/CD95). Nature 1995; 373: 438-441.
33. Fearnhead HO, Dinsdale D, Cohen GM. An interleukin-1β-converting enzyme-like protease is a common mediator of apoptosis in thymocytes. FEBS Lett 1995; 375: 283-288.
34. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehgara S, Nagai K. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin-and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 1996; 156: 3678-3686.
35. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nuñez G, Krammer PH, Peter ME, Debatin KM. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997; 57: 4956-4964.
36. Froelich CJ, Hanna WL, Poirier GG, Duriez PJ, D'Amours D, Salvesen GS, Alnemri ES, Earnshaw WC, Shah GM. Granzyme B/perforin-mediated apoptosis of Jurkat cells results in cleavage of poly(ADP-ribose) polymerase to the 89-kDa apoptotic fragment and less abundant 64-kDa fragment. Biochem Biophys Res Commun 1996; 227: 658-665.
37. Schmidt-Wolf IG, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta BA, Tsuruo T, Huhn D, Negrin RS. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 1996; 169: 85-90.
38. Frost P, Ng CP, Belldegrun A, Bonavida B. Immunosensitation of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol 1997; 180: 70-83.
39. McGahon A, Costa Pereira AP, Daly L, Cotter TG. Chemotherapeutic drug-induced apoptosis in human leukemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol 1998; 101: 539-547.
40. Eischen CM, Kottke TJ, Martins LM, Guriqbal SB, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 1997; 90: 935-943.